These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10642672)

  • 1. HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases.
    Pujol RM; Domingo P; Xavier-Matias-Guiu ; Francia E; Sanbeat MA; Alomar A; Vazquez G
    J Am Acad Dermatol; 2000 Feb; 42(2 Pt 1):193-8. PubMed ID: 10642672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.
    Temple ME; Koranyi KI; Nahata MC
    Ann Pharmacother; 2003 Sep; 37(9):1214-8. PubMed ID: 12921501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lipodystrophy and hyperglycemia produced by protease inhibitors].
    Reus S; Arroyo E; Boix V; Portilla J
    An Med Interna; 2000 Mar; 17(3):123-6. PubMed ID: 10804634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
    Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F;
    Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters.
    Maher B; Lloyd J; Wilkins EG; Fraser WD; Back D; Park BK; Pirmohamed M
    Antivir Ther; 2004 Dec; 9(6):879-87. PubMed ID: 15651746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
    Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
    Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV protease inhibitor-related lipodystrophy syndrome.
    Carr A
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S135-42. PubMed ID: 10860898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding and treating protease paunch.
    Vazquez E
    Posit Aware; 1999; 10(4):59-63. PubMed ID: 11366810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of protease inhibitor therapy.
    Bernasconi E
    AIDS Read; 1999 Jul; 9(4):254-6, 259-60, 266-9. PubMed ID: 12737115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
    Martínez E; Domingo P; Ribera E; Milinkovic A; Arroyo JA; Conget I; Pérez-Cuevas JB; Casamitjana R; de Lazzari E; Bianchi L; Montserrat E; Roca M; Burgos R; Arnaiz JA; Gatell JM
    Antivir Ther; 2003 Oct; 8(5):403-10. PubMed ID: 14640387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.
    Hadigan C; Meigs JB; Corcoran C; Rietschel P; Piecuch S; Basgoz N; Davis B; Sax P; Stanley T; Wilson PW; D'Agostino RB; Grinspoon S
    Clin Infect Dis; 2001 Jan; 32(1):130-9. PubMed ID: 11118392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fat redistribution syndrome in patients infected with HIV: measurements of body shape abnormalities.
    Gerrior J; Kantaros J; Coakley E; Albrecht M; Wanke C
    J Am Diet Assoc; 2001 Oct; 101(10):1175-80. PubMed ID: 11678488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metabolic complications associated with use of protease inhibitors].
    Mosnier-Pudar H
    Ann Med Interne (Paris); 2000 Jun; 151(4):278-82. PubMed ID: 10922955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dysmetabolic syndrome related to HIV-1 protease inhibitors. Review of the literature and personal data].
    Urso R; Croce GF; Tubili C; De Marco M; La Scala P; Luglio D; Narciso P
    Recenti Prog Med; 2000 Feb; 91(2):78-85. PubMed ID: 10748653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
    Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
    Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study.
    Schwenk A; Breuer JP; Kremer G; Römer K; Bethe U; Franzen C; Fätkenheuer G; Salzberger B
    Eur J Med Res; 2000 Oct; 5(10):443-8. PubMed ID: 11076786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.